A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Trial of the Safety, Efficacy, and Pharmacokinetics of ANA598 Administered With Pegylated Interferon and Ribavirin in Treatment-Naive Genotype 1 Patients With Chronic Hepatitis C Infection.

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Trial of the Safety, Efficacy, and Pharmacokinetics of ANA598 Administered With Pegylated Interferon and Ribavirin in Treatment-Naive Genotype 1 Patients With Chronic Hepatitis C Infection.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Setrobuvir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Anadys Pharmaceuticals
  • Most Recent Events

    • 13 Nov 2012 Additional lead trial center identified as reported by ClinicalTrials.gov.
    • 31 Jan 2012 Actual end date Aug 2011 added as reported by ClinicalTrials.gov.
    • 31 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top